ACM
EWTX icon

Aster Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Aster Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.57K Sell
211
-99
-32% -$3.41K ﹤0.01% 677
2026
Q1 		$6.82K Buy
310
+158
+104% +$4.56K ﹤0.01% 654
2025
Q4 		$3.77K Buy
+152
New +$3.05K ﹤0.01% 905
2025
Q1 		– Sell
-229
Closed -$6.11K – 1378
2024
Q4 		$6.11K Buy
+229
New +$7.29K ﹤0.01% 835

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Aster Capital Management's EWTX Position: Q2 2026 in Review

Aster Capital Management reduced its Edgewise Therapeutics (EWTX) stake by 32% in Q2 2026, selling an estimated $3.41K and leaving 211 shares worth $8.57K. The position accounts for ﹤0.01% of the portfolio, ranked #677.

Aster Capital Management first reported a position in EWTX in Q4 2024 and has held it in 4 quarters since. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Aster Capital Management held 211 shares of Edgewise Therapeutics worth $8.57K as of Q2 2026.
  • Aster Capital Management sold 99 Edgewise Therapeutics shares in Q2 2026, an estimated $3.41K.
  • Edgewise Therapeutics made up ﹤0.01% of Aster Capital Management's portfolio in Q2 2026, its #677 holding.
  • Aster Capital Management first reported a position in Edgewise Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.